Latest news

Thumbnail image for NICE asks Tesaro to submit CDF application for Zejula

NICE asks Tesaro to submit CDF application for Zejula

Tesaro has been asked by NICE to submit a proposal for Zejula use on the National Health Service via the Cancer Drugs Fund for maintenance treatment of patients with relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.

9th February 2018

Thumbnail image for ViiV kicks off PhIII trial of two-drug HIV regimen

ViiV kicks off PhIII trial of two-drug HIV regimen

ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.

9th February 2018

Thumbnail image for Biogen reveals Tysabri failure in stroke trial

Biogen reveals Tysabri failure in stroke trial

Biogen has confirmed that it will not pursue further development of Tysabri in acute ischemic stroke (AIS) after a mid-stage study missed primary and secondary efficacy goals.

9th February 2018

Thumbnail image for GSK happy with 3 percent rise in 2017 sales

GSK happy with 3 percent rise in 2017 sales

GlaxoSmithKline has reported a sales hike of 3 percent at constant exchange rates (CER*) for 2017, after growth was recorded across all of its three global businesses.

8th February 2018

Thumbnail image for Theravance Ireland signs deal with Janssen Biotech

Theravance Ireland signs deal with Janssen Biotech

Theravance Biopharma Ireland has signed a global co-development and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions, including ulcerative colitis and Crohn’s disease.

8th February 2018

Thumbnail image for Scotland’s TCB inks CAR-T deal with Japan’s NIPRO

Scotland’s TCB inks CAR-T deal with Japan’s NIPRO

Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical activities.

7th February 2018

Previous  --   12 13 14 15 16 17 18 19 20 21   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download